|
MAFG expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.39669994961389E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.19479994973449E-09 |
| Normal-vs-Stage2 |
1.50430000001034E-06 |
| Normal-vs-Stage3 |
1.88719995186659E-09 |
| Normal-vs-Stage4 |
3.65099994681373E-09 |
| Stage1-vs-Stage2 |
8.404800E-01 |
| Stage1-vs-Stage3 |
3.003800E-01 |
| Stage1-vs-Stage4 |
3.104400E-01 |
| Stage2-vs-Stage3 |
3.828000E-01 |
| Stage2-vs-Stage4 |
3.886800E-01 |
| Stage3-vs-Stage4 |
9.646200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.42639996983485E-09 |
| Normal-vs-AfricanAmerican |
8.80250000001581E-07 |
| Normal-vs-Asian |
2.5957999999493E-06 |
| Caucasian-vs-AfricanAmerican |
7.434000E-01 |
| Caucasian-vs-Asian |
2.968400E-01 |
| AfricanAmerican-vs-Asian |
6.697000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.16509945924781E-10 |
| Normal-vs-Female |
7.42100003670032E-09 |
| Male-vs-Female |
1.111800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.56880000498927E-08 |
| Normal-vs-Age(41-60Yrs) |
2.71680000718533E-09 |
| Normal-vs-Age(61-80Yrs) |
4.96800045546308E-10 |
| Normal-vs-Age(81-100Yrs) |
6.759400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.566000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.772000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.838800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.132800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.686000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.808000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.150500E-02 |
| Classical-VS-Follicular |
8.900800E-01 |
| Classical-VS-Other |
9.559500E-02 |
| Classical-VS-Normal |
1.70020000300752E-08 |
| Tall-VS-Follicular |
1.003240E-01 |
| Tall-VS-Other |
3.923800E-01 |
| Tall-VS-Normal |
5.37830002755868E-10 |
| Follicular-VS-Other |
4.381700E-02 |
| Follicular-VS-Normal |
1.39600000004236E-07 |
| Other-VS-Normal |
9.04770000031974E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.29349994551598E-09 |
| Normal-vs-N1 |
1.30259999453486E-08 |
| N0-vs-N1 |
6.477600E-01 |
|
|
